View
237
Download
1
Tags:
Embed Size (px)
DESCRIPTION
Dr. Michael Schröter
Citation preview
Roche Pharma Research & Early Development (pRED) Accessing external innovation Michael Schröter – Nov 2012
2
Transforming deals and external innovation into medicines
Partner agreement In-licensed *2011 sales figures
CHF m CHF m
Mabthera/Rituxan 6,005 Actemra/RoActemra 618
Avastin 5,292 Xolair 603
Herceptin 5,253 Valcyte/Cymevene 569
Lucentis 1,523 Pulmozyme 492
Pegasys 1,438 Activase/TNKase 453
Xeloda 1,354 Tamiflu 359
Tarceva 1,251 Mircera 344
CellCept 991 Nutropin 317
NeoRec/Epogin 896 Madopar 294
Bonviva/Boniva 696 Neutrogin 278
CHF m CHF m
Mabthera/Rituxan 6,005 Actemra/RoActemra 618
Avastin 5,292 Xolair 603
Herceptin 5,253 Valcyte/Cymevene 569
Lucentis 1,523 Pulmozyme 492
Pegasys 1,438 Activase/TNKase 453
Xeloda 1,354 Tamiflu 359
Tarceva 1,251 Mircera 344
CellCept 991 Nutropin 317
NeoRec/Epogin 896 Madopar 294
Bonviva/Boniva 696 Neutrogin 278
3
Global Access to Talent Diversity
pRED Strategy – How We Win Translating science into medical innovation for patients
3
Scientific opportunity and medical need
Translational Medicine Expertise
Leading Technology Platforms
External R&D
Innovation Network
Our key capabilities to deliver a diverse and high value portfolio
Exploratory Areas
Excel in our Focus Areas
Neuroscience Oncology
CV & Metabolism Virology
Our focus Three pillars to execute our strategy
pRED research and translational medicine hubs A new mode for collaboration with academia
4
Pre-clinical Development
Clinical Development
Pharma
• new targets / new molecules • cuttting edge pathway & biology
research
• selected patient populations • cutting edge technologies (e.g.
imaging
Research Clinic Partner (universities, institutes, etc.)
Translational R&D Hub
Establish, manage and lead a strong networks of academic partnerships to deliver on pRED projects and to enhance the pRED portfolio
5
Technology partnerships
Singapore • Network of 26 academic partner institutes,
several programs, e.g. angiogenesis • SERI – R&D partnership in Ophthalmology • Virtual R&D unit with financial reimbursements
Netherlands Imaging Hub • Collaborative Hub of 3 world-class academic
imaging sites
French R&D Institute • Access to academic innovation
network with positive impact on key European affiliate
Montreal Heart Institute • Cardiovascular center of excellence
Swiss University Network • Basel, neuroscience cognition research
and ETH Zurich, joint Rx / Dx hub
pRED External Innovation Network Complementing our capabilities and amplifying our ability to innovate
Harvard • iPSC (stem cells)
PTC Therapeutics • Advanced treatment options for
spinal muscular atrophy
Baylor • Therapeutic vaccines
Geneva University • Proteomics and
pathway analysis
Yissum • Novel pathways, β-cell stem
cells discovery, CV risk biomarkers
Mt Sinai • Novel screening approaches
in Virology
Technology partnerships Translational hubs
6
Roche Institute for Research & Translational Medicine A new R&D structure dedicated to partnerships
• 48 partnerships with Academic Centers • pRED team based in France : Academic Alliance
scientists dedicated to local collaborative R&D projects
• 6 Roche Employees + 11 PhD or post-docs
Nanotechnologies Biomarkers
Key features of value for DTAs/ Functions
7
Dutch Imaging Network Allowing pRED to access leading imaging capabilities in Europe
• World class for imaging antibody distribution
• Excellent clinical and pre-clinical imaging facilities and expertise
• A novel mode of working together: close scientific collaboration
• Excellence in imaging for oncology, neuroscience and inflammation
Nijmegen
Amsterdam
Creating a strategic alliance with Key features of value for DTAs/ Functions
Through the Dutch hub we are able to ‘do more, with less’ by leveraging external capabilities rather than utilizing our own expenditure to build up our own capabilities
Groningen
8
Diagnostic development
Drug development
Evaluation of biomarkers vs. clinical response
Phase III
Companion Diagnostic Development GLP Biomarker Assay Development
Replication Discovery & hypothesis generation
Launch with Companion Diagnostic
Phase I Phase III Early Development Research Phase II
Personalised healthcare as a key enabler Innovation across the value chain
9 9
We Innovate Healthcare
10
Roche Group – structure
Pharmaceuticals Diagnostics